Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Gastroenterologie Clinique Et Biologique
|
January 2, 2008
Colorectal cancer screening program: cost effectiveness of systematic recall letters
Karim Tifratene, François Eisinger, Yves Rinaldi, et al.
Journal of Robotic Surgery
|
August 12, 2020
Robotic hepatic parenchymal transection: a two-surgeon technique using ultrasonic dissection and irrigated bipolar coagulation
Antoine Camerlo, Cloé Magallon, Charles Vanbrugghe, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)
|
June 20, 2022
Sylvie Arlotto, Stéphanie Gentile, Yves Rinaldi, et al.
European Journal of Gastroenterology & Hepatology
|
December 9, 2021
Colorectal cancer screening by fecal immunochemical test or colonoscopy in France: how many people are actually covered? Focus on the Provence-Alpes-Côte d'Azur region
Jean-François Seitz, David Lapalus, Sylvie Arlotto, et al.
The Oncologist
|
August 8, 2019
Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study
Frédérique Retornaz, Olivier Guillem, Frédérique Rousseau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, et al.
British Journal of Cancer
|
November 23, 2021
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials
Daniel Pietrasz, Shufang Wang-Renault, Julien Taieb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial
Laetitia Dahan, Nicolas Williet, Karine Le Malicot, et al.
Eclinicalmedicine
|
June 8, 2026
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France)
Julien Taieb, Simon Pernot, Frédéric Thuillier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 6, 2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
Yves Rinaldi, Anne-Laure Pointet, Faiza Khemissa Akouz, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Gastroenterologie Clinique Et Biologique
|
January 2, 2008
Colorectal cancer screening program: cost effectiveness of systematic recall letters
Karim Tifratene, François Eisinger, Yves Rinaldi, et al.
Journal of Robotic Surgery
|
August 12, 2020
Robotic hepatic parenchymal transection: a two-surgeon technique using ultrasonic dissection and irrigated bipolar coagulation
Antoine Camerlo, Cloé Magallon, Charles Vanbrugghe, et al.
Sante Publique (Vandoeuvre-Les-Nancy, France)
|
June 20, 2022
Sylvie Arlotto, Stéphanie Gentile, Yves Rinaldi, et al.
European Journal of Gastroenterology & Hepatology
|
December 9, 2021
Colorectal cancer screening by fecal immunochemical test or colonoscopy in France: how many people are actually covered? Focus on the Provence-Alpes-Côte d'Azur region
Jean-François Seitz, David Lapalus, Sylvie Arlotto, et al.
The Oncologist
|
August 8, 2019
Predicting Chemotherapy Toxicity and Death in Older Adults with Colon Cancer: Results of MOST Study
Frédérique Retornaz, Olivier Guillem, Frédérique Rousseau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, et al.
British Journal of Cancer
|
November 23, 2021
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials
Daniel Pietrasz, Shufang Wang-Renault, Julien Taieb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 21, 2021
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial
Laetitia Dahan, Nicolas Williet, Karine Le Malicot, et al.
Eclinicalmedicine
|
June 8, 2026
Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61-FUNGEMAX trial (France)
Julien Taieb, Simon Pernot, Frédéric Thuillier, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 6, 2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)
Yves Rinaldi, Anne-Laure Pointet, Faiza Khemissa Akouz, et al.
Page
of 3